We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+26.22%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.23B
AUM Growth
+$240M
Cap. Flow
+$116M
Cap. Flow %
9.38%
Top 10 Hldgs %
61.25%
Holding
137
New
51
Increased
28
Reduced
20
Closed
23

Top Buys

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$70.5M
2
CELG
Celgene Corp
CELG
+$37.6M
3
RPRX
Repros Therapeutics Inc.
RPRX
+$27.9M
4
TSRO
TESARO, Inc.
TSRO
+$21.7M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$19.9M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$106M
2
BIIB icon
Biogen
BIIB
+$49.8M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$31.3M
4
STML
Stemline Therapeutics, Inc.
STML
+$16.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 76.94%
2 Financials 0.01%
3 Consumer Staples 0.01%
4 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MOH icon
101
Molina Healthcare
MOH
$10.4B
$128K 0.01%
3,590
+3,040
+553% +$112K
KYTH
102
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$126K 0.01%
+2,765
New +$82.7K
ZLTQ
103
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$124K 0.01%
+13,703
New +$102K
CUTR
104
DELISTED
Cutera, Inc.
CUTR
$110K 0.01%
12,400
-35,469
-74% -$335K
AXGN icon
105
Axogen
AXGN
$2.2B
$20K ﹤0.01%
+4,500
New +$16.5K
BIIB icon
106
Biogen
BIIB
$30.9B
– –
-231,282
Closed -$49.8M
CRIS icon
107
Curis
CRIS
$9.71M
– –
-696
Closed -$4.44M
BGMS
108
Bio Green Med Solution Inc
BGMS
$4.86M
– –
0
– -$1.03M
DGX icon
109
Quest Diagnostics
DGX
$26B
– –
-325
Closed -$20K
ELV icon
110
Elevance Health
ELV
$81.5B
– –
-255
Closed -$21K
GILD icon
111
PUT
Gilead Sciences
GILD
$165B
– –
0
– -$2.48M
HCA icon
112
HCA Healthcare
HCA
$90.6B
– –
-308,560
Closed -$11.1M
KMDA icon
113
Kamada
KMDA
$404M
– –
-394,860
Closed -$4.41M
REGN icon
114
Regeneron Pharmaceuticals
REGN
$72.9B
– –
-139,310
Closed -$31.3M
SRPT icon
115
CALL
Sarepta Therapeutics
SRPT
$1.64B
– –
0
– -$10.5M
SRPT icon
116
PUT
Sarepta Therapeutics
SRPT
$1.64B
– –
0
– -$14.9M
UNH icon
117
UnitedHealth
UNH
$382B
– –
-315
Closed -$21K
VIRX
118
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-276
Closed -$301K
SGEN
119
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
– –
0
– -$1.57M
ENDP
120
DELISTED
Endo International plc
ENDP
– –
-530
Closed -$19K
EPZM
121
DELISTED
Epizyme, Inc
EPZM
– –
-18,000
Closed -$506K
HRC
122
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
– –
-590
Closed -$20K
CEMP
123
DELISTED
Cempra, Inc.
CEMP
– –
-200,000
Closed -$1.55M
SQNM
124
DELISTED
SEQUENOM INC NEW
SQNM
– –
-985,180
Closed -$4.15M
BMR
125
DELISTED
BIOMED REALTY TRUST INC
BMR
– –
-50,000
Closed -$1.01M
2 3 4
5
6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2013 Portfolio in Review

As of Q3 2013, Perceptive Advisors held 137 positions worth $1.23B, up 24% from $992M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Perceptive Advisors deployed $116M of net new capital in Q3 2013, opening 51 new positions and adding to 28 existing holdings. Its largest new stake was ONYX PHARMACEUTICALS INC: 556,944 shares worth $69.5M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 80% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Aegerion Pharmaceuticals, an estimated $106M trimmed.

  • Perceptive Advisors's largest Q3 2013 buy was ONYX PHARMACEUTICALS INC: 556,944 shares worth $69.5M.
  • Perceptive Advisors added most to Celgene Corp in Q3 2013, an estimated $37.6M increase.
  • Perceptive Advisors's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $106M.
  • Perceptive Advisors fully exited Biogen in Q3 2013, selling an estimated $49.8M.
  • Perceptive Advisors's ten largest holdings make up 61% of its $1.23B portfolio in Q3 2013.
  • Perceptive Advisors opened 51 new positions and closed 23 in Q3 2013.
  • Perceptive Advisors's portfolio value rose 24% quarter-over-quarter to $1.23B.

Based on Perceptive Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.